

Highlights of This Issue 1031

REVIEW

- 1033** Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor
Lisa Paysan, Léo Piquet, Frédéric Saltel, and Violaine Moreau

CELL DEATH AND SURVIVAL

- 1045** Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment
Daniel P. Nguyen, Peter L. Xiong, He Liu, Samuel Pan, Wilhem Leconet, Vincent Navarro, Ming Guo, Jonathan Moy, Sae Kim, Marigdalena K. Ramirez-Fort, Jaspreet S. Batra, and Neil H. Bander

CHROMATIN, EPIGENETICS, AND RNA REGULATION

- 1054** Cooperative Dynamics of AR and ER Activity in Breast Cancer
Nicholas C. D'Amato, Michael A. Gordon, Beatrice Babbs, Nicole S. Spoelstra, Kiel T. Carson Butterfield, Kathleen C. Torkko, Vernon T. Phan, Valerie N. Barton, Thomas J. Rogers, Carol A. Sartorius, Anthony Elias, Jason Gertz, Britta M. Jacobsen, and Jennifer K. Richer

DNA DAMAGE AND REPAIR

- 1068** Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein
Antonia A. Nemeč, Korie B. Bush, Jamie B. Towle-Weicksel, B. Frazier Taylor, Vincent Schulz, Joanne B. Weidhaas, David P. Tuck, and Joann B. Sweasy

GENOMICS

- 1078** Transcription Factor KLF5 Binds a Cyclin E1 Polymorphic Intronic Enhancer to Confer Increased Bladder Cancer Risk
Jillian M. Pattison, Valeriya Posternak, and Michael D. Cole

METABOLISM

- 1087** Extracellular ATP a New Player in Cancer Metabolism: NSCLC Cells Internalize ATP *In Vitro* and *In Vivo* Using Multiple Endocytic Mechanisms
Yanrong Qian, Xuan Wang, Yunsheng Li, Yanyang Cao, and Xiaozhuo Chen

ONCOGENES AND TUMOR SUPPRESSORS

- 1097** Ubiquitin Ligase, Fbw7, Targets CDX2 for Degradation via Two Phosphodegron Motifs in a GSK3 β -Dependent Manner
Yogesh Kumar, Nidhi Shukla, Gatha Thacker, Isha Kapoor, Savita Lochab, Madan Lal Brahma Bhatt, Naibedya Chattopadhyay, Sabyasachi Sanyal, and Arun Kumar Trivedi
- 1110** *Erc1* Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a *Tp53* Context-Specific Manner
Mladen Jokić, Ignacija Vlačić, Miriam Rinneburger, Niklas Klümper, Judith Spiro, Wenzel Vogel, Anne Offermann, Christiane Kumpers, Christian Fritz, Anna Schmitt, Arina Riabinska, Maike Wittersheim, Sebastian Michels, Luka Ozretić, Alexandra Florin, Daniela Welcker, Mehmet Deniz Akyuz, Michael Nowak, Martin Erkel, Jürgen Wolf, Reinhard Büttner, Björn Schumacher, Jürgen Thomale, Thorsten Persigehl, David Maintz, Sven Perner, and Hans Christian Reinhardt

- 1124** Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGF β 1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p
Hardik R. Mody, Sau Wai Hung, Mohammad AlSaggar, Jazmine Griffin, and Rajgopal Govindarajan

SIGNAL TRANSDUCTION

- 1136** Exosome-mediated Transfer of α v β 3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype
Amrita Singh, Carmine Fedele, Huimin Lu, Marja T. Nevalainen, James H. Keen, and Lucia R. Languino

Table of Contents

1147 Systemic Ablation of MMP-9 Triggers Invasive Growth and Metastasis of Pancreatic Cancer via Dereglulation of IL6 Expression in the Bone Marrow


Barbara Grünwald, Jennifer Vandooren, Michael Gerg, Kaarin Ahomaa, Annique Hunger, Sonja Berchtold, Sophia Akbareian, Susanne Schaten, Percy Knolle, Dylan R. Edwards, Ghislain Opdenakker, and Achim Krüger

1159 Melatonin Represses Metastasis in *Her2*-Positive Human Breast Cancer Cells by Suppressing RSK2 Expression

Lulu Mao, Whitney Summers, Shulin Xiang, Lin Yuan, Robert T. Dauchy, Amberly Reynolds, Melissa A. Wren-Dail, David Pointer, Tripp Frasch, David E. Blask, and Steven M. Hill

ABOUT THE COVER

In this issue, D'Amato and colleagues (page 1054) provide a new understanding of the interplay between androgen receptor and estrogen receptor, the two most widely-expressed hormone receptors in breast cancer. The image on the cover is a visualization of estrogen receptor ChIP-seq signal following 1 hour estradiol treatment alone or in the presence of the anti-androgens enzalutamide or MJC13. Columns represent estradiol alone (left), estradiol plus enzalutamide (center), or estradiol plus MJC13 (right). By inhibiting nuclear localization of androgen receptor, both anti-androgens significantly diminish ER chromatin binding, explaining their ability to inhibit estrogen-driven breast cancer in preclinical models.



Molecular Cancer Research

14 (11)

Mol Cancer Res 2016;14:1031-1169.

Updated version Access the most recent version of this article at:
<http://mcr.aacrjournals.org/content/14/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mcr.aacrjournals.org/content/14/11>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.